An official website of the United States government
September 29, 2026 Edition
News
Antiviral drug did not improve Long COVID symptoms
A clinical trial for Long COVID found that treating patients with a common antiviral drug for up to 25 days did not improve symptoms.
News
tRNA treatment may help restore cystic fibrosis proteins
Lipid nanoparticles delivering engineered transfer RNA restored functional proteins in cell and animal models of cystic fibrosis.
News
Bacterial infection may alter developing gut
C. difficile bacteria caused lasting changes to cells in the intestines of newborn mice.
Displaying 526 - 532 of 912
Biosensor advances drug discovery
Researchers developed a sensor that helped them identify a psychedelic-related drug with antidepressant-like effects that wasn’t hallucinogenic.
Boosting brain's waste removal system could improve Alzheimer's outcomes
A study in mice showed that antibody therapies targeting amyloid-beta protein were more effective after enhancing the brain's waste drainage system.
The genetic effects of Chernobyl radiation exposure
Studies of people exposed to radiation from the Chernobyl accident and their children further our understanding of the genetic effects of radiation exposure.
Uncovering the origins of brown fat
Researchers identified previously unknown origins of brown fat, which burns energy to create heat for the body.
Oral antiviral drug effective against COVID-19 in hamsters
An oral antiviral drug called MK-4482 inhibited SARS-CoV-2 replication in hamsters. It is currently being tested in people.
Lack of sleep in middle age may increase dementia risk
People who slept six hours or less per night in their 50s and 60s were more likely to develop dementia later in life.
Targeted treatments for small-cell lung cancer
A rapid screening process identified a two-drug combination that shrank small-cell lung tumors, which are often fatal within weeks of recurrence.